Search

Chandramouli S Chiruta

from San Diego, CA
Age ~50
Get Report
Also known as:
Chandramou Chiruta, Chiruta Chandramouli
Phone and address:
4178 Decoro St, San Diego, CA 92122
(858) 412-3066
Connected to:
Pramode Chiruvolu, 39Adrian C Chis, 56Dan Chis, 56Ileana L Chis, 49Lucian Chis, 60Ann L Chisam, 62Jamal R Chisam, 38Jeanette A Chisam, 54Jeffrey F Chisam, 62Mary L Chisam, 113

Chandramouli Chiruta Phones & Addresses

  • 4178 Decoro St, San Diego, CA 92122 (858) 412-3066
  • 4158 Decoro St APT 5, San Diego, CA 92122

Resumes

Resumes

Chandramouli Chiruta Photo 1

Senior Scientist-Ii

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Salk Institute for Biological Studies since Oct 2009
Research Associate
The Scripps Research Institute (TSRI), La Jolla, CA, USA Feb 2008 - Oct 2009
Postdoctoral Research Associate
University of Alberta, Edmonton, CANADA Jan 2006 - Jan 2008
Postdoctoral Fellow
Education:
Indian Institute of Chemical Technology (IICT) 2000 - 2005
Ph. D, Organic Chemistry
Chandramouli Chiruta Photo 2

Chandramouli Chiruta

View page
Location:
San Diego, CA
Work:
The Scripps Research Institute
Ra
Chandramouli Chiruta Photo 3

Chandramouli Chiruta

View page
Location:
San Diego, CA
Industry:
Research
Work:
The Scripps Research Institute
RA
Chandramouli Chiruta Photo 4

Ra At Tsri

View page
Position:
RA at TSRI
Location:
Greater San Diego Area
Industry:
Pharmaceuticals
Work:
TSRI
RA

Publications

Us Patents

Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20220332698, Oct 20, 2022
Filed:
Jan 22, 2021
Appl. No.:
17/155577
Inventors:
- San Diego CA, US
Chi Ching Mak - San Diego CA, US
Brian Walter Eastman - San Diego CA, US
Jianguo Cao - San Diego CA, US
Venkataiah Bollu - San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
International Classification:
C07D 401/14
C07D 471/10
C07D 417/04
C07D 413/14
C07D 405/14
C07D 409/14
C07D 487/08
C07D 401/04
C07D 491/048
C07D 417/14
C07D 487/04
C07D 471/08
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20230104155, Apr 6, 2023
Filed:
Oct 6, 2021
Appl. No.:
17/495281
Inventors:
- San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Brian Joseph Hofilena - San Diego CA, US
Joseph Timothy Marakovits - Encinitas CA, US
Chandramouli Chiruta - San Diego CA, US
Chi Ching Mak - San Diego CA, US
Jianguo Cao - San Diego CA, US
International Classification:
C07D 401/14
C07D 401/04
C07D 405/14
C07D 413/14
C07D 417/14
C07D 455/02
C07D 487/04
C07D 487/08
C07D 491/08
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20200339536, Oct 29, 2020
Filed:
Dec 26, 2019
Appl. No.:
16/727053
Inventors:
- San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Brian Joseph Hofilena - San Diego CA, US
Joseph Timothy Marakovits - Encinitas CA, US
Chandramouli Chiruta - San Diego CA, US
Chi Ching Mak - San Diego CA, US
Jianguo Cao - San Diego CA, US
International Classification:
C07D 401/14
C07D 401/04
C07D 405/14
C07D 413/14
C07D 417/14
C07D 455/02
C07D 487/04
C07D 487/08
C07D 491/08
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20200299263, Sep 24, 2020
Filed:
Dec 4, 2019
Appl. No.:
16/703321
Inventors:
- San Diego CA, US
Chi Ching Mak - San Diego CA, US
Brian Walter Eastman - San Diego CA, US
Jianguo Cao - San Diego CA, US
Venkataiah Bollu - San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
International Classification:
C07D 401/14
C07D 471/10
C07D 417/04
C07D 413/14
C07D 405/14
C07D 409/14
C07D 487/08
C07D 401/04
C07D 491/048
C07D 417/14
C07D 487/04
C07D 471/08
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Indazole Containing Macrocycles And Therapeutic Uses Thereof

View page
US Patent:
20190382402, Dec 19, 2019
Filed:
Jun 13, 2019
Appl. No.:
16/440284
Inventors:
- San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
Brian Joseph Hofilena - San Diego CA, US
International Classification:
C07D 471/04
C07D 401/12
C07D 401/14
A61P 35/00
A61P 11/00
Abstract:
Indazole macrocycle compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

5-Heteroaryl Substituted Indazole-3-Carboxamides And Preparation And Use Thereof

View page
US Patent:
20190263821, Aug 29, 2019
Filed:
Feb 22, 2019
Appl. No.:
16/283366
Inventors:
- San Diego CA, US
Chi Ching Mak - San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Brian Joseph Hofilena - San Diego CA, US
Brian Walter Eastman - San Diego CA, US
Jianguo Cao - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
Venkataiah Bollu - San Deigo CA, US
International Classification:
C07D 487/04
C07D 403/04
C07D 403/14
C07D 401/14
C07D 413/14
C07D 405/14
C07D 417/14
Abstract:
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20190233396, Aug 1, 2019
Filed:
Sep 13, 2018
Appl. No.:
16/130842
Inventors:
- San Diego CA, US
Chi Ching Mak - San Diego CA, US
Brian Walter Eastman - San Diego CA, US
Jianguo Cao - San Diego CA, US
Venkataiah Bollu - San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
International Classification:
C07D 401/14
C07D 487/04
C07D 417/14
C07D 491/048
C07D 401/04
C07D 487/08
C07D 471/08
C07D 405/14
C07D 413/14
C07D 417/04
C07D 471/10
C07D 409/14
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

6-(6-Membered Heteroaryl & Aryl)Isoquinolin-3-Yl Carboxamides And Preparation And Use Thereof

View page
US Patent:
20190125740, May 2, 2019
Filed:
Oct 26, 2018
Appl. No.:
16/172553
Inventors:
- San Diego CA, US
Chi Ching Mak - San Diego CA, US
Brian Joseph Hofilena - San Diego CA, US
Gopi Kumar Mittapalli - San Diego CA, US
Brian Walter Eastman - San Diego CA, US
Jianguo Cao - San Diego CA, US
Venkataiah Bollu - San Diego CA, US
Chandramouli Chiruta - San Diego CA, US
International Classification:
A61K 31/4725
A61P 25/16
A61P 25/28
A61P 35/00
A61P 29/00
A61P 7/00
Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
Control profile
Chandramouli S Chiruta from San Diego, CA, age ~50 Get Report